Opus Genetics, Inc. carries no debt; cash flow comfortably covers obligations.

Opus Genetics, Inc.'s free cash flow has decreased 37.84% from $-25.58M last year to $-35.25M, signaling decreasing performance

Opus Genetics, Inc.'s debt to equity ratio is -0.57, signaling that the company spent its equity and risk bankruptcy.

Opus Genetics, Inc. has insufficient data to evaluate this check.

Opus Genetics, Inc. has negative EBITDA, making leverage ratio unreliable

Opus Genetics, Inc. carries no debt; interest obligations are fully covered.

Opus Genetics, Inc.'s profit margin has decreased (70.49%) in the last year from -523.40% to -892.36%, signaling decreasing performance

Opus Genetics, Inc.'s short-term assets of $50.04M exceed its short-term liabilities of $7.78M

Opus Genetics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Opus Genetics, Inc.'s return on equity of 6.07K%, is higher than 15.00%, indicating good performance

Opus Genetics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Opus Genetics, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

Opus Genetics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Opus Genetics, Inc. has negative free cash flow, indicating cash burn

Opus Genetics, Inc.'s yearly earnings has increased -13.80% since last year from $-57.53M to $-49.59M, signaling increasing performance

Opus Genetics, Inc.'s yearly revenue has increased 29.15% since last year from $10.99M to $14.20M, signaling increasing performance

ROIC -74.91% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Opus Genetics, Inc.'s 3-year revenue CAGR of -29.11% is negative, indicating declining revenue over the past 3 years

Opus Genetics, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Opus Genetics, Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

Opus Genetics, Inc. has insufficient data to evaluate this check.

Opus Genetics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Opus Genetics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Opus Genetics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Opus Genetics, Inc. has insufficient data to evaluate this check.

Opus Genetics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Opus Genetics, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Opus Genetics, Inc. has a price-to-sales ratio of 27.56x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue